Aim To estimate the radiation dose delivered from patients injected with yttrium-90 (Y-90)-labelled tiuxetan (Zevalin) to parents and the general population, comparing different techniques. Methods The radiation dose delivered from a group of eight patients injected with Y-90-Zevalin to treat recurrent lymphoma was measured. The data obtained with the Monte Carlo simulation test were compared with the experimental measurements obtained with an ionization chamber detector and with a crystal Nal(TI) detector. Results A good correlation was found between the Monte Carlo simulation test and the ionization chamber detector results: the air kerma dose rate was 4.2 +/- 0.1 and 4.4 +/- 0.8 mu Gy/h, respectively (r = 0.9, P < 0.01). Moreover, m...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increas...
Purpose: Treatment of hepatic malignancies with Y-90 microsphere therapy can require a “split-dose” ...
Aim To estimate the radiation dose delivered from patients injected with yttrium-90 (Y-90)-labelled ...
OBJECTIVE: To assess the impact of nonuniform dose distribution within lesions and tumor-involved or...
Aim To investigate the variation in biological effective dose (BED) produced by the uncertainty in a...
Purpose: Radioembolization is a novel treatment which utilizes the liver\u27s unique dual system blo...
Several updated Monte Carlo (MC) codes are available to perform calculations of voxel S values for r...
AIM of this study was the assessment of the radiation exposure from preparation and application of (...
Radioiodine therapy is an effective method for treating thyroid cancer carcinoma, but it has some af...
Purpose: To assess out-of-field doses in radiotherapy treatments of pediatric patients, using Monte ...
Aim: In our multicentric ongoing phase I activity escalation study, 90Y-labeled ibritumomab tiuxetan...
Introduction: 90Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-do...
PURPOSE: Yttrium-90 ((90) Y) microsphere radioembolization enables selective internal radiotherapy f...
X-ray Spectra are generated for a tungsten target X-ray source operating at 120 kVp for dose predict...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increas...
Purpose: Treatment of hepatic malignancies with Y-90 microsphere therapy can require a “split-dose” ...
Aim To estimate the radiation dose delivered from patients injected with yttrium-90 (Y-90)-labelled ...
OBJECTIVE: To assess the impact of nonuniform dose distribution within lesions and tumor-involved or...
Aim To investigate the variation in biological effective dose (BED) produced by the uncertainty in a...
Purpose: Radioembolization is a novel treatment which utilizes the liver\u27s unique dual system blo...
Several updated Monte Carlo (MC) codes are available to perform calculations of voxel S values for r...
AIM of this study was the assessment of the radiation exposure from preparation and application of (...
Radioiodine therapy is an effective method for treating thyroid cancer carcinoma, but it has some af...
Purpose: To assess out-of-field doses in radiotherapy treatments of pediatric patients, using Monte ...
Aim: In our multicentric ongoing phase I activity escalation study, 90Y-labeled ibritumomab tiuxetan...
Introduction: 90Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-do...
PURPOSE: Yttrium-90 ((90) Y) microsphere radioembolization enables selective internal radiotherapy f...
X-ray Spectra are generated for a tungsten target X-ray source operating at 120 kVp for dose predict...
International audienceWe compared the radiation-absorbed dose obtained from a two dimensional (2D) p...
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increas...
Purpose: Treatment of hepatic malignancies with Y-90 microsphere therapy can require a “split-dose” ...